Posted by Michael Wonder on 29 Mar 2018
Agenda for 4 April TC meeting
29 March 2018 - HAS has posted the agenda for the next scheduled TC meeting.
The Transparency Commission will consider the reimbursement of:
- Sofosbuvir (Sovaldi)
- Ledipasvir with sofosbuvir (Harvoni)
- Maraviroc (Celsentri)
- Nilotinib hydrochloride monohydrate (Tasigna)
- Ixekizumab (Taltz)
- Ocrelizumab (Ocrevus)
